Boston Scientific Corp (BSX)
Health Care · Health Care Equipment · US stock · S&P 500 component
$44.39
▲ +0.25 (0.57%)
Fair valueFair
$48 +9.2% to fair value
$24fair band $29–$68$73
Day's range
$43.89 – $44.83
52-week range
$41.39 – $105.65
About Boston Scientific Corp
Boston Scientific develops, manufactures and sells medical devices used in minimally invasive procedures. Its products treat heart rhythm disorders, blocked arteries, structural heart conditions, kidney stones, digestive and pelvic disorders, and chronic pain. It sells mainly to hospitals and physicians through a direct sales force worldwide. Revenue comes from device sales, many of which are single-use items used repeatedly in procedures, and from related equipment and services.
Revenue over the last twelve months was $21.0 billion, with growth of 16.5% a year over three years. The operating margin stands at 19.8%. The return on invested capital is shown as 10%. Net debt to EBITDA is 2.2 times. The company does not pay a dividend. Its X-Ray Score is 64 out of 100. These numbers describe past results and current financial position, and they are shown for reference only.
Written with AI from public information and the filing figures on this page, then checked automatically for unsupported numbers. It can contain mistakes: read the company's own filings below before relying on it.
Price chart
52-wk range $41.39 – $105.65Volume 12,409,700Daily, split-adjusted
Vitals
Market cap$65.5B
52-week range$41.39 – $105.65
Volume (last day)12,409,700
P/E (TTM)18.0
EBIT / EV yield5.3%
Free-cash-flow yield5.5%
Dividend yieldNo dividend
Revenue (TTM)$21.0B
Net income (TTM)$3.7B
Operating margin19.8%
Return on capital10.1%
Debt incl. leases$12.6B
Cash & securities$539M
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies like Apple). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
$48model spread $45 – $52
Fair
+9.2% to fair value
Equal blend of three models: peer multiples, a fundamentals-adjusted multiple (growth, ROIC and margin) and a 10-year DCF scaled to the market's average. Earnings-power value (no growth) is a floor and not part of the blend. Model uncertainty is High, so the safety margin is 40%.
Multiples use through-the-cycle earnings (0.62x of the last twelve months)
Peak-cycle earnings: the current operating margin is more than 1.5x its 7-year average, so the fair value range is widened
Price $44
Undervalued < $29Fair $29 – $68Overvalued > $68
10-year DCF (market-scaled)
$66
Peer multiples
$34
Earnings power floor (not blended)
$13
Fundamentals-adjusted multiple
$45
Growth the price implies
10.5%/yr
A model estimate, not a price target or recommendation. Inputs: risk-free 5.09%, equity risk premium 4.23% (Damodaran). How it works.
What this means
Weak business, fairly priced
The price sits inside our fair-value band. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.
Valuation
Fair
68/100
Priced about in line with its sector.
See the numbers →
EBIT / EV yield5.3%
Free-cash-flow yield5.5%
Fair value vs price1.1×
Growth
Strong
89/100
Growing faster than most of its sector.
See the numbers →
Revenue growth (3y)16.5%
EPS growth (3y)62.8%
Growth consistency100%
Profitability
Weak
45/100
Earns lower returns on its capital than most peers.
See the numbers →
Return on invested capital10.1%
Operating margin19.8%
Gross profitability32.5%
Financial health
Fair
55/100
Balance sheet is in typical shape for its sector.
See the numbers →
Piotroski F-Score8 / 9
Net debt / EBITDA2.2×
Interest cover11.4×
Dividends
None
–/100
Pays no dividend.
See the numbers →
Quarterly results: last 6 quarters
+20.9%
Mar '25
+22.8%
Jun '25
+20.3%
Sep '25
+15.9%
Dec '25
+11.6%
Mar '26
+7.5%
Jun '26
Revenue against the same quarter a year earlier. Latest quarter revenue $5.4B, diluted EPS $0.61.
Compare with peers
RMD Resmed Inc73 DXCM Dexcom Inc71 PODD Insulet Corp69 IDXX Idexx Laboratories Inc67Other Health Care Equipment companies by X-Ray Score.
Fundamentals checklist
● 6 Good · ● 8 Average · ● 2 BadCash quality
Earnings backed by cashBad
Free-cash-flow yieldAverage
Risk models
Altman Z''Average
Piotroski F-ScoreGood
Growth
EPS growth (3y)Good
Free-cash-flow growth (3y)Good
Revenue growth (3y)Good
Growth consistencyGood
Balance sheet
Current ratioBad
Net debt / EBITDAAverage
Interest coverAverage
Valuation
Fair value vs priceAverage
EBIT / EV yieldGood
Profitability
Return on invested capitalAverage
Operating marginAverage
Gross profitabilityAverage
Each check is graded against the company's sector, not a fixed number. Checklist score 60/100.
Financials
| FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|
| Revenue | $11.9B | $12.7B | $14.2B | $16.7B | $20.1B |
| Operating income | $1.2B | $1.6B | $2.3B | $2.6B | $3.6B |
| Net income | $1.0B | $698M | $1.6B | $1.8B | $2.9B |
| Operating cash flow | $1.9B | $1.5B | $2.5B | $3.4B | $4.5B |
| Operating margin | 10.1% | 13.0% | 16.5% | 15.5% | 18.0% |
| Free cash flow | $1.3B | $938M | $1.8B | $2.6B | $3.7B |
| Diluted EPS | $0.69 | $0.45 | $1.07 | $1.25 | $1.94 |
Fiscal years, from SEC filings.
Technical summary
Daily
Bearish
5 bullish · 2 neutral · 9 bearish
Weekly
Strongly bearish
1 bullish · 1 neutral · 10 bearish
Monthly
Strongly bearish
1 bullish · 0 neutral · 7 bearish
Moving averages (daily)
| SMA 10 | 42.96 | Bullish |
| EMA 10 | 43.44 | Bullish |
| SMA 20 | 43.45 | Bullish |
| EMA 20 | 43.66 | Bullish |
| SMA 50 | 46.09 | Bearish |
| EMA 50 | 45.10 | Bearish |
| SMA 100 | 46.00 | Bearish |
| EMA 100 | 48.76 | Bearish |
| SMA 200 | 59.10 | Bearish |
| EMA 200 | 58.19 | Bearish |
Oscillators (daily)
| RSI (14) | 52.51 | Neutral |
| MACD (12, 26) | -0.51 | Bearish |
| Momentum (12) | 1.70 | Bullish |
| Stochastic %K (14) | 87.21 | Bearish |
| Williams %R (14) | -12.79 | Bearish |
| CCI (20) | 88.28 | Neutral |
Pivot points (classic, last session)
S3 42.97 | S2 43.43 | S1 43.91 | Pivot 44.37 | R1 44.85 | R2 45.31 | R3 45.79 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
BSX SEC filings
7 Oct 2026
8-KSEC EDGAR
Director or officer change; Other events
23 Sep 2026
8-KSEC EDGAR
Director or officer change
8 Sep 2026
8-KSEC EDGAR
Current report
26 Aug 2026
8-KSEC EDGAR
Other events
3 Aug 2026
10-QSEC EDGAR
Quarterly report
29 Jul 2026
8-KSEC EDGAR
Results of operations
27 Jul 2026
8-KSEC EDGAR
Exit or restructuring costs
18 May 2026
8-KSEC EDGAR
Other events
Where the numbers come from
Statements SEC EDGAR filings (10-K, 10-Q), quarters derived from year-to-date figures.
Prices end-of-day closes, split-adjusted.
Industry inputs beta, multiples and equity risk premium from Damodaran Online (NYU Stern).
StocksXray is for education only and is not financial advice. Scores and fair values are model estimates from public filings and carry uncertainty.